Pyoderma gangrenosum
Pyoderma gangrenosum ose fa'ama'i e seasea ona tupu i le pa'u, lea e avea ai pustules tiga po'o nodule ma papala e faasolosolo ona tupu. Pyoderma gangrenosum e le fa'ama'i. Togafitiga e mafai ona aofia ai corticosteroids, cyclosporin, poʻo monoclonal antibodies eseese. E ui lava e mafai ona aʻafia ai tagata o soʻo se matua, e tele lava ina aʻafia ai tagata i le 40 ma le 50s o latou tausaga.
☆ I le 2022 Stiftung Warentest i'uga mai Siamani, o le fa'amalieina o tagata fa'atau i ModelDerm sa na'o sina maualalo ifo nai lo fa'atalanoaga telemedicine totogi.
I luga o le vae o le tagata e maua i le ulcerative colitis.
References
Pyoderma gangrenosum ose ma'i e seasea maua e mafua ai le ma'i papala e mumu pe violē pito. O lo'o fa'avasegaina ose fa'ama'i fa'ama'i ma ose vaega o se vaega e ta'ua o le neutrophilic dermatoses. O le mafua'aga o le pyoderma gangrenosum e lavelave, e a'afia ai fa'afitauli fa'atasi ma fa'alavelave fa'anatinati ma fetuutuuna'i i tagata e fa'atupu fa'ama'i. Talu ai nei, na taulaʻi atu ai tagata suʻesuʻe i le follicule o lauulu e avea o se amataga amata o le maʻi.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum ose ma'i e seasea maua ile pa'u e mafua ai le ma'i papala. E ui tatou te le malamalama atoatoa i lona mafuaʻaga, ae tatou te iloa e aofia ai le faʻateleina o gaioiga a nisi o sela puipuia. O le togafitia o le maʻi e leʻo faigofie. E iai a matou vailaʻau eseese e taofia ai le puipuiga o le tino poʻo le suia o lana gaioiga. Faatasi ai ma nei mea, matou te taulai atu foi i le togafitia o manuʻa ma le puleaina o tiga. Corticosteroids ma cyclosporine e masani lava o le filifiliga muamua mo togafitiga, ae talu ai nei, ua tele suʻesuʻega i le faʻaaogaina o togafitiga faʻapitoa e pei ole TNF-α inhibitors. O nei meaola fa'aola ua fa'ateleina le fiafia, aemaise lava i tagata mama'i ma isi tulaga fa'ama'i, ma o lo'o fa'aaogaina muamua i le fa'agasologa o fa'ama'i.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
